Header Logo

Connection

HELEN HESLOP to Genetic Therapy

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about Genetic Therapy.
HELEN HESLOP
Connection Strength
1.585
Genetic Therapy
  1. Gene therapy. Cytotherapy. 2007; 9(6):519-20.
    View in: PubMed
    Score: 0.177
  2. Gene therapy for paediatric leukaemia. Expert Opin Biol Ther. 2001 Jul; 1(4):663-74.
    View in: PubMed
    Score: 0.121
  3. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.
    View in: PubMed
    Score: 0.113
  4. Gene therapy of pediatric leukemia. Clin Lab Med. 2000 Mar; 20(1):183-95, x.
    View in: PubMed
    Score: 0.110
  5. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 04 10; 36(11):1128-1139.
    View in: PubMed
    Score: 0.095
  6. Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther. 2018 01 03; 26(1):1-2.
    View in: PubMed
    Score: 0.095
  7. Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
    View in: PubMed
    Score: 0.077
  8. Reply to S. Yuan et al. J Clin Oncol. 2014 Sep 01; 32(25):2820-1.
    View in: PubMed
    Score: 0.075
  9. Immunotherapy: opportunities, risks and future perspectives. Cytotherapy. 2014 Apr; 16(4 Suppl):S120-9.
    View in: PubMed
    Score: 0.073
  10. Cytokine gene transfer in the therapy of malignancy. Baillieres Clin Haematol. 1994 Mar; 7(1):135-51.
    View in: PubMed
    Score: 0.073
  11. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol. 2014 Mar 10; 32(8):798-808.
    View in: PubMed
    Score: 0.072
  12. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9.
    View in: PubMed
    Score: 0.063
  13. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
    View in: PubMed
    Score: 0.062
  14. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
    View in: PubMed
    Score: 0.039
  15. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.034
  16. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.
    View in: PubMed
    Score: 0.033
  17. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. Arch Pediatr. 2002 Mar; 9(3):289-306.
    View in: PubMed
    Score: 0.032
  18. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer. 2001 Sep 01; 93(5):706-13.
    View in: PubMed
    Score: 0.031
  19. Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. 2001 Jun; 8(12):930-7.
    View in: PubMed
    Score: 0.030
  20. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
    View in: PubMed
    Score: 0.028
  21. Gene and cell transfer for specific immunotherapy. Vox Sang. 1998; 74 Suppl 2:87-90.
    View in: PubMed
    Score: 0.024
  22. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997 Dec 10; 8(18):2301-38.
    View in: PubMed
    Score: 0.024
  23. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Dec 01; 7(18):2287-313.
    View in: PubMed
    Score: 0.022
  24. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1996 Aug 20; 7(13):1621-47.
    View in: PubMed
    Score: 0.022
  25. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant. 2015 Feb; 21(2):202-24.
    View in: PubMed
    Score: 0.019
  26. T-cell immunotherapy: looking forward. Mol Ther. 2014 Sep; 22(9):1564-74.
    View in: PubMed
    Score: 0.019
  27. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.018
  28. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.